After Novartis (NVS) announced an agreement to acquire Avidity Biosciences (RNA), including its proprietary Antibody Oligonucleotide Conjugate platform for targeted RNA delivery to the muscle, for $72 per share in cash, Morgan Stanley reminded investors that Dyne Therapeutics (DYN) has also developed the proprietary FORCE platform designed to deliver RNA therapeutics to muscle and that Avidity is a key competitor. The firm, which believes the acquisition provides positive readthrough to Dyne, has an Overweight rating and $48 price target on the shares.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DYN:
- Dyne Therapeutics up 37% after Avidity gets bought
- Dyne Therapeutics Positioned for Growth with FORCE Platform and Key Upcoming Catalysts
- Dyne Therapeutics: Promising Advancements in Neuromuscular Treatments Drive Buy Rating
- Dyne Therapeutics downgraded to Perform at Oppenheimer following additional data
- Dyne Therapeutics downgraded to Perform from Outperform at Oppenheimer